Molecure (WAR:MOC) EBIT per Share: zł-1.24 (TTM As of Sep. 2025)

What is Molecure EBIT per Share?

Molecure WAR:MOC -2.01% 29 EBIT per Share is zł-1.24 as of Sep. 2025. GuruFocus rates WAR:MOC with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, Molecure ranks worse than 84.47% on this metric.

Molecure's EBIT per Share for the three months ended in Sep. 2025 was zł-0.31. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was zł-1.24.

During the past 3 years, the average EBIT per Share Growth Rate was -17.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Molecure's EBIT per Share or its related term are showing as below:

WAR:MOC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -86.1 Med: -38.1 Max: -11.9
Current: -17.5

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Molecure was -11.90% per year. The lowest was -86.10% per year. And the median was -38.10% per year.

WAR:MOC's 3-Year EBIT Growth Rate is ranked worse than
84.47% of 1172 companies
in the Biotechnology industry
Industry Median: 15.35 vs WAR:MOC: -17.50

Molecure's EBIT for the three months ended in Sep. 2025 was zł-5.24 Mil.

Molecure (WAR:MOC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Molecure EBIT per Share Related Terms

Molecure EBIT per Share Historical Data

* Premium members only.

The historical data trend for Molecure's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure EBIT per Share Chart

Molecure Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

5.32

-0.98

-1.09

-1.69

-1.55

Molecure Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25
EBIT per Share	Get a 7-Day Free Trial															-0.37	-0.52	-0.26	-0.16	-0.31

29GF Score

Molecure SA WAR:MOC

EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Molecure EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Molecure's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-31.288	/	20.203
=	-1.55

Molecure's EBIT per Share for the quarter that ended in Sep. 2025 is calculated as

	EBIT per Share		(Q: Sep. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.236	/	16.989
=	-0.31

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-1.24

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of zł-1.24 mean?

Molecure (WAR:MOC) has a EBIT per Share of zł-1.24 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Molecure and its competitors. According to the industry distribution chart, Molecure ranks #990 out of 1172 companies in the Biotechnology industry, placing it in the top 84.5%.

Is Molecure's EBIT per Share too high?

Molecure's current EBIT per Share is zł-1.24. Based on the distribution chart, Molecure ranks #990 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecure has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does Molecure's EBIT per Share compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Molecure ranks #990 out of 1172 companies for EBIT per Share. This places Molecure in the lower half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Biotechnology company?

The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Molecure and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecure's current EBIT per Share is zł-1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Molecure stock overvalued right now?

Molecure (WAR:MOC) has a current EBIT per Share of zł-1.24. The current EBIT per Share is zł-1.24. Molecure's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For Molecure (WAR:MOC), the current EBIT per Share is zł-1.24 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Industry Healthcare Biotechnology

Comparable Companies WAR:MAB WAR:NNG WAR:PTG WAR:SVE WAR:URT WAR:RDG WAR:PHR WAR:PUR WAR:GX1 WAR:SCS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 1B1:Germany

Address Zwirki i Wigury 101, Warsaw, POL, 02-089

Website https://www.molecure.com

Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.

29GF Score

Get the complete analysis for WAR:MOC

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.85

Price

View WAR:MOC Analysis

See EBIT per Share data for all stocks →